A Phase 1 interventional study of Tazemetostat in Hepatic Impairment and Advanced Malignant Solid Tumor, sponsored by Epizyme, Inc.. Terminated at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 1, Interventional, and Treatment
Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat.
The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function.
An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment.
The trial will also study the safety of the study drug in participants (how well it is tolerated).
The study will be conducted in 2 parts for subjects with advanced malignancies and either normal liver function, or advanced malignancies and moderate, or severe hepatic impairment. Subjects in Part 1 of the study will receive a single oral, 800 mg dose of tazemetostat on Day 1 and Day 15. In addition, the subjects will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 5 to Day 14. Blood samples for PK analysis will be obtained on Day 1 through Day 4 and again on Day 15 through Day 18. Part 1 ends on Day 18.
Subjects continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles beginning on Day 19 until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. Subjects must have an end of study visit for safety assessment 30 days after the last dose of tazemetostat or prior to initiation of a subsequent anticancer therapy, whichever occurs first. Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying procedure manuals (i.e., laboratory, pharmacy, ECG manuals). Such manuals will provide the site personnel with administrative and detailed technical information that does not impact subject safety.
Epizyme, Inc. is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
First submitted before Epizyme, Inc. became part of Ipsen.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Participants will receive a single oral 800 mg dose on day 1, and twice daily from day 5 to day 14. Participants will return to the clinical study unit on an out-patient basis from day 15 to day 18. A single oral 800 mg dose of tazemetostat will be administered on day 15. Part 2: Will begin on day 19 and participants continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles.
Drug: Tazemetostat
Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle. Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity.
Also known as: EPZ-6438, IPN60200, Tazverik®
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following single dose administration. Pharmacokinetic (PK) parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of AUC0-inf of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Part 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Part 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose Administration
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Part 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Part 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)
Blood samples were collected at specified timepoints for the assessment of fu of tazemetostat and its metabolite EPZ-6930 following single dose and multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
Time frame: Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this study drug. A serious AE was an AE that occurred during any study phase (i.e., baseline, treatment, washout, or follow-up), and at any dose of the study drug, comparator, or placebo, that fulfilled one or more of the following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect or was an important medical event that jeopardized the participant or required medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the day of the first dose of study drug through 30 days after the end of study drug.
Time frame: From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
This phase I, 2-part, open-label study was conducted in participants with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment at 18 sites in 5 countries. Study was terminated following Sponsor's decision to discontinue tazemetostat treatment in all active clinical trials and expanded access programs based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
| Milestone | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Started | 10 | 8 |
| Participants entered part 2 | 9 | 4 |
| Completed | 0 | 0 |
| Not completed | 10 | 8 |
| Withdrew: Radiologic progression | 5 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Clinical progression | 1 | 1 |
| Withdrew: Unacceptable toxicity/adverse event | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other | 0 | 1 |
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following single dose administration. Pharmacokinetic (PK) parameters were assessed using non-compartmental data analysis method.
| hour*nanogram per milliliter (h*ng/mL) | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 8030 ± 6990 | 13900 ± 3570 |
| EPZ-6930 | 7520 ± 3580 | 8060 ± 3270 |
Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| h*ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 4520 ± 1790 | 9550 ± 5040 |
| EPZ-6930 | 11100 ± 4360 | 13600 ± 4310 |
Blood samples were collected at specified timepoints for the assessment of AUC0-inf of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
| h*ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 8050 ± 6990 | 14000 ± 3600 |
| EPZ-6930 | 7590 ± 3620 | 8210 ± 3310 |
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
| h*ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 5700 ± 4440 | 7580 ± 2120 |
| EPZ-6930 | 4020 ± 1880 | 3360 ± 1600 |
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| h*ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 3290 ± 1490 | 5720 ± 2530 |
| EPZ-6930 | 6140 ± 2190 | 7390 ± 2110 |
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
| ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 1580 ± 1030 | 2020 ± 725 |
| EPZ-6930 | 868 ± 425 | 714 ± 387 |
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| ng/mL | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 1120 ± 559 | 1850 ± 772 |
| EPZ-6930 | 1400 ± 587 | 1560 ± 568 |
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
| hour | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 1.50 (0.950 to 6.10) | 1.78 (0.967 to 5.83) |
| EPZ-6930 | 1.97 (1.43 to 7.75) | 2.97 (1.45 to 5.97) |
Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| hour | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 1.45 (0.967 to 4.00) | 1.00 (0.950 to 1.50) |
| EPZ-6930 | 1.93 (1.05 to 4.00) | 1.50 (0.983 to 3.77) |
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.
| hour | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 6.37 ± 1.00 | 10.9 ± 4.62 |
| EPZ-6930 | 11.0 ± 4.06 | 13.6 ± 3.93 |
Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| hour | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat | 10.3 ± 5.03 | 16.7 ± 9.21 |
| EPZ-6930 | 15.2 ± 3.82 | 18.1 ± 6.87 |
Blood samples were collected at specified timepoints for the assessment of fu of tazemetostat and its metabolite EPZ-6930 following single dose and multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.
| ratio | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Tazemetostat: Day 1: 3 hours post-dose | 0.122 ± 0.0243 | 0.126 ± 0.0253 |
| Tazemetostat: Day 15: Pre-dose | 0.114 ± 0.0192 | 0.118 ± 0.0180 |
| Tazemetostat: Day 15: 3 hours post-dose | 0.117 ± 0.0242 | 0.124 ± 0.0168 |
| EPZ-6930: Day 1: 3 hours post-dose | 0.412 ± 0.0643 | 0.421 ± 0.0621 |
| EPZ-6930: Day 15: Pre-dose | 0.394 ± 0.0496 | 0.385 ± 0.0662 |
| EPZ-6930: Day 15: 3 hours post-dose | 0.393 ± 0.0764 | 0.418 ± 0.0462 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this study drug. A serious AE was an AE that occurred during any study phase (i.e., baseline, treatment, washout, or follow-up), and at any dose of the study drug, comparator, or placebo, that fulfilled one or more of the following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect or was an important medical event that jeopardized the participant or required medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the day of the first dose of study drug through 30 days after the end of study drug.
| Participants | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Any TEAE | 10 | 7 |
| Any TESAE | 3 | 5 |
Collected over AEs were collected from first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks. Deaths were collected from first dose of study drug (Day 1) up to end of follow up for death for each participant, approximately 269 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Hepatic Function Cohort | 4/10 (40%) | 3/10 (30%) | 10/10 (100%) |
| Moderate Hepatic Impairment Cohort | 3/8 (37.5%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Event | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| Cholangitis acuteHepatobiliary disorders | 0/10 | 1/8 |
| CholangitisHepatobiliary disorders | 0/10 | 1/8 |
| JaundiceHepatobiliary disorders | 0/10 | 1/8 |
| SepsisInfections and infestations | 0/10 | 1/8 |
| Intracranial tumour haemorrhageNervous system disorders | 0/10 | 1/8 |
| Status epilepticusNervous system disorders | 0/10 | 1/8 |
| General physical health deteriorationGeneral disorders | 0/10 | 1/8 |
| HypokalaemiaMetabolism and nutrition disorders | 0/10 | 1/8 |
| COVID-19 pneumoniaInfections and infestations | 1/10 | 0/8 |
| Atrial fibrillationCardiac disorders | 1/10 | 0/8 |
| Event | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort |
|---|---|---|
| NauseaGastrointestinal disorders | 1/10 | 4/8 |
| DizzinessNervous system disorders | 3/10 | 0/8 |
| Abdominal painGastrointestinal disorders | 1/10 | 2/8 |
| VomitingGastrointestinal disorders | 0/10 | 2/8 |
| HypokalaemiaMetabolism and nutrition disorders | 0/10 | 2/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/10 | 2/8 |
| Blood alkaline phosphatase increasedInvestigations | 0/10 | 2/8 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/10 | 2/8 |
| FatigueGeneral disorders | 2/10 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 2/10 | 0/8 |
Safety population consisted of all participants who received at least one dose or partial dose of study drug.
| Age, Continuous(years) | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Mean | 64.3 ± 12.06 | 63.1 ± 8.76 | 63.8 ± 10.43 |
| Sex: Female, Male(Participants) | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 8 | 6 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 3 |
| Not Hispanic or Latino | 7 | 5 | 12 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Race/Ethnicity, Customized(Participants) | Normal Hepatic Function Cohort | Moderate Hepatic Impairment Cohort | Total |
|---|---|---|---|
| White | 8 | 5 | 13 |
| Black or African American | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
| Not Reported | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Mar 2025, 61 months.
Results were first posted in Nov 2026, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tazemetostat